The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
UNITY BIOTECHNOLOGY, INC. | COM | 91381U200 | 1,939,297 | 1,004,817 | SH | SOLE | 0 | 0 | 1,004,817 | ||
DENALI THERAPEUTICS, INC. | COM | 24823R105 | 8,181,604 | 381,249 | SH | SOLE | 0 | 0 | 381,249 | ||
GOSSAMER BIO, INC. | COM | 38341P102 | 7,351,023 | 8,055,916 | SH | SOLE | 0 | 0 | 8,055,916 | ||
SINGULAR GENOMICS SYSTEMS, INC. | COM | 82933R100 | 1,747,886 | 3,798,926 | SH | SOLE | 0 | 0 | 3,798,926 | ||
ERASCA, INC. | COM | 29479A108 | 23,548,330 | 11,055,554 | SH | SOLE | 0 | 0 | 11,055,554 | ||
REVOLUTION MEDICINES, INC. | COM | 76155X100 | 92,736,493 | 3,233,490 | SH | SOLE | 0 | 0 | 3,233,490 | ||
VERVE THERAPEUTICS, INC. | COM | 92539P101 | 28,002,797 | 2,008,809 | SH | SOLE | 0 | 0 | 2,008,809 |